Global Duchenne Muscular Dystrophy Drugs Market Size To Exceed USD 18.48 Billion by 2035 | CAGR 14.80%
Category: HealthcareGlobal Duchenne Muscular Dystrophy Drugs Market Size To Exceed USD 18.48 Billion by 2035
According to a Research Report Published By Spherical Insights & Consulting, The Global Duchenne Muscular Dystrophy Drugs Market Size is Expected to Grow from USD 4.05 Billion in 2024 to USD 18.48 Billion by 2035, at a CAGR of 14.80% during the Forecast Period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 245 pages with 122 Market data tables and figures & charts from the report on the “Global Duchenne Muscular Dystrophy Drugs Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Molecular Based, Steroid Based, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.” Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/duchenne-muscular-dystrophy-drugs-market
Pharmaceutical Therapies are the main focus of the Market Size for medications for Duchenne Muscular Dystrophy (DMD), a rare genetic disorder that causes progressive muscle degradation. It consists of injectable and oral exon-skipping drugs, corticosteroids, and gene therapies. Prominent companies invest in innovative medications to improve patient outcomes. Distribution occurs through hospitals, retail, and online pharmacies, and demand is influenced by awareness, healthcare infrastructure, and reimbursement regulations. The primary factors propelling the market's rise are increased funding for R&D, the rising incidence of duchenne muscular dystrophy drugs and the development of genetic research. Growing research and development (R&D) expenditures are a key driver of the duchenne muscular dystrophy drugs market since they spur innovation and expedite the discovery of novel therapies. Governments, non-profits, and pharmaceutical companies are providing financial support for research and development in this field. However, high treatment expenses, few curative choices, regulatory obstacles, delayed approvals, genetic complexity, a lack of financing for research, and difficulties with accessibility.
The molecular based segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the treatment, the duchenne muscular dystrophy drugs market is divided into molecular based, steroid based, non-steroidal anti-inflammatory drugs (NSAIDs), and others. Among these, the molecular based segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Market growth is being driven by rising DMD disease incidence and rising demand for molecular-based treatments that target the genetic basis of DMD.
The hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the distribution channel, the duchenne muscular dystrophy drugs market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Hospital pharmacies have a strong distribution channel and are used to market these specialty medications.
North America is expected to hold the majority share of the global duchenne muscular dystrophy drugs market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global duchenne muscular dystrophy drugs market during the forecast period. The U.S. has a dominant position in the North American market due to the high prevalence of DMD and substantial funding for research in anticipation of the launch of promising pipeline medicines.
Asia Pacific is anticipated to grow at the fastest pace in the global duchenne muscular dystrophy drugs market during the forecast period. The increasing R&D activity in countries like China, India, and Japan, as well as the emphasis on creating innovative treatments by several biotech companies and academic institutions, are additional factors driving growth in the Asia Pacific area.
Europe is predicted to hold a significant share of the duchenne muscular dystrophy drugs market throughout the estimated period. In addition, Germany's ability to get innovative DMD medications to the market is strengthened by the presence of top pharmaceutical companies and cooperative initiatives between academic institutions and industry stakeholders.
Major vendors in the global duchenne muscular dystrophy drugs market are Aurobindo Pharma, Catalyst Pharmaceuticals, Inc., PTC Therapeutics. Inc., FibroGen, Inc., NS Pharma, INC., Sarepta Therapeutics, Inc., Capricor Therapeutics, Inc., ITALFARMACO S.p.A., EspeRare Foundation, Santhera Pharmaceuticals, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In March 2024, To treat DMD, Catalyst Pharmaceuticals, Inc. announced that the medication AGAMREE is now available in the United States. To better patient therapy for the uncommon DMD condition, the medication was introduced for patients older than two.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the duchenne muscular dystrophy drugs market based on the below-mentioned segments:
Global Duchenne Muscular Dystrophy Drugs Market, By Treatment
- Molecular Based
- Steroid Based
- Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- Others
Global Duchenne Muscular Dystrophy Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Duchenne Muscular Dystrophy Drugs Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?